SCHEMBL18005195

SCHEMBL18005195

N#Cc1[nH]nnc1-c1nc(-c2ccc(Cl)cc2)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ CYP19A1 P11511 2/20 0.47
▸ NPC1 O15118 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ CDC25A P30304 1/20 0.42
▸ CDC25B P30305 1/20 0.42
▸ CDC25C P30307 1/20 0.42
▸ SREBF2 Q12772 1/20 0.42
▸ MAPT P10636 6/20 0.41
▸ ATM Q13315 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ LTA4H P09960 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16399142 0.90 KDM4E (0.49) RAB9AKDM4ELMNASMN1; SMN2CYP19A1
SCHEMBL18005117 0.86 ABL1 (0.42) RAB9AKDM4ENPC1MEN1KMT2A
SCHEMBL18005252 0.84 KDM4E (0.48) KDM4EMEN1KMT2ACDC25ACDC25B
SCHEMBL16398838 0.81 ALOX5 (0.42) RAB9AKDM4ECYP19A1MEN1KMT2A
SCHEMBL18005017 0.80 CYP1A1 (0.35) RAB9AKDM4ELMNASMN1; SMN2CYP19A1
SCHEMBL16399594 0.79 EIF4E (0.48) RAB9AKDM4ENPC1MEN1KMT2A
SCHEMBL18005020 0.79 KDM4E (0.42) RAB9AKDM4ELMNASMN1; SMN2NPC1
SCHEMBL16399551 0.79 EIF4E (0.39) —
SCHEMBL17969183 0.79 ERBB2 (0.49) KDM4ELMNAALDH1A1GAAL3MBTL1
SCHEMBL18005835 0.79 GAA (0.44) KDM4ELMNAMEN1KMT2AALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 RAB9A 4775/4885KDM4E 2681/4885LMNA 4192/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 RAB9A 4775/4885KDM4E 2681/4885LMNA 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback